Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2024 | Story André Damons | Photo supplied
From top (left to right): Dr Angélique Lewies (researcher from the Robert WM Frater Cardiovascular Research Centre within the UFS Department of Cardiothoracic Surgery), Zurika Murray (behavioural geneticist from the UFS Department of Genetics), Dr Marieka Gryzenhout (C-rated scientist and Senior Lecturer in the Department of Genetics), and Dr Jaco Wentzel (serves as the pharmaceutical industry partner and consultant for the project at FARMOVS).

In an effort to advance drug discovery and disease research, researchers from the University of the Free State (UFS), the Central University of Technology (CUT), and FARMOVS, a clinical research company associated with the UFS, is developing innovative 3D cell culture models using 3D printed mini bioreactors.

This interdisciplinary project, led by Dr Angélique Lewies, researcher from the Robert WM Frater Cardiovascular Research Centre (Frater Centre) within the UFS Department of Cardiothoracic Surgery, is creating more accurate and human-like models for this purpose, reducing the need for animal testing, and improving the safety and effectiveness of new treatments.

The project was initiated to address the challenges associated with current 3D cell culture techniques, which are often expensive and complex. Recognising the need for a more cost-effective and user-friendly solution, the researchers embarked on this collaboration to develop a novel 3D cell culture system. By making these advanced techniques more accessible, the team aims to enhance the reliability of drug testing and significantly reduce the reliance on animal experiments. This innovative approach not only promises to cut costs but also promotes ethical research practices in the scientific community.

Dr Lewies, whose research specialises in cardio-oncology (relationship between cancer treatment and heart health), particularly in understanding and preventing damage to cardiac cells caused by chemotherapy, leads the cell biology aspects of the project, focusing on the cultivation of 3D cancer spheroid and organoid cultures.

According to her, the project focuses on creating 3D cell cultures, known as spheroids and organoids, that mimic human tissues more closely. These 3D models can improve the reliability of drug testing and reduce the need for animal experiments, aligning with the 3R principles: Reduction, Replacement, and Refinement.

Creating a versatile platform

“Traditional drug discovery and disease studies often rely on flat (2D) cell cultures and animal models. While animal models are essential for understanding disease and testing drug safety, they don't always predict how humans will respond, and their use raises ethical concerns.

“We aim to develop affordable and efficient 3D-printed mini bioreactors for growing these advanced cell cultures. These bioreactors will be designed to fit into existing cell culture labs, making them accessible to researchers. By leveraging the cutting-edge 3D printing technology at CUT's Centre for Rapid Prototyping and Manufacturing (CRPM), the team hopes to create a versatile platform for various research applications,” says Dr Lewies.

She is joined in this project by UFS colleagues; Zurika Murray, a behavioural geneticist, and her colleague from the Department of Genetics, Dr Marieka Gryzenhout, a C-rated scientist and Senior Lecturer. Dr Jaco Wentzel from FARMOVS. is also involved in the project. Dr Wentzel serves as the pharmaceutical industry partner and consultant for the project. With experience in cellular biology and pharmaceuticals, he ensures that the new 3D cell culture models meet industry standards and can be effectively used in drug development. Dr Wentzel’s role is crucial in bridging the gap between academic research and practical application in the pharmaceutical industry.

Goals

According to Dr Lewies, this project aims to create more accurate and ethical models for drug testing and improving the development of new treatments. By combining expertise from engineering, biology, and mycology, the team is set to revolutionise how diseases are studied, and medicines developed. Funded by the CUT and UFS Joint Research Programme, this initiative promises to foster innovation and lead to new research collaborations.

“Cardiac cell damage, known as cardiotoxicity, can lead to serious cardiovascular diseases and is a major reason why some drugs are removed from the market. By developing 3D cancer spheroids and cardiac organoids (mini heart models), my team aims to find ways to prevent this cardiotoxicity while enhancing the effectiveness of chemotherapy drugs.

“Additionally, they are exploring the cardiotoxic effects of natural products, such as medicinal plants and mushrooms, which show potential for both anticancer and cardio-protective properties,” says Dr Lewies.

Experts

Murray is interested in how the psychedelic compounds psilocybin and psilocin affect the brain with her research focusing on the epigenome of genes within the serotonin pathway, which could explain the therapeutic potential of these compounds. “As part of this project, Murray will work with the Frater Centre to develop neuronal organoids (mini brain models) using the 3D mini-bioreactor platform.

“This will allow her to investigate the effects of psilocybin and psilocin on brain function, which have shown promise in treating mental health disorders like depression and anxiety, aiming to understand how these substances might help treat mental health issues,” says Dr Lewies.

Dr Gryzenhout brings her expertise in mycology and is responsible for cultivating medicinal mushrooms used in the project. Dr Gryzenhout's research focuses on the genetic characterisation of medicinal mushrooms and evaluating their therapeutic potential. These mushrooms produce a variety of bioactive compounds with therapeutic benefits, including anticancer activities, heart protection, and immune system support.

Her team is also approved by the South African Health Products Regulatory Authority (SAHPRA) to research the controlled psychedelic compounds psilocybin and psilocin.

Drug Discovery Goals

The project’s long-term focus is on potentially discovering new drugs to prevent and treat heart and brain diseases. Specifically, the team is working on developing therapies for cardio-oncology and neurological applications. In the realm of cardio-oncology, the goal is to find treatments that prevent cardiac cell damage and downstream cardiovascular diseases caused by cancer therapies, while still effectively targeting cancer cells. For neurological applications, the researchers are exploring the potential of drugs derived from medicinal mushrooms, including those with psychedelic properties, to treat conditions like depression, anxiety, and other mental health disorders.

News Archive

Einstein's gravitational waves as creative as Bach's music, says UFS physicist
2016-02-19

Description: Gravitational waves  Tags: Gravitational waves

Profile of the gravitational waves of the colliding black holes.

Prof Pieter Meintjes, Affiliated Researcher in the Department of Physics at the University of the Free State, welcomed the work done by the Laser Interferometer Gravitational-Wave Observatory (LIGO) science team.
 
For the first time, researchers from two of the American Ligo centres, in Washington and Louisiana respectively, observed gravitational waves directly, 100 years after Albert Einstein said they existed. "My study field in astrophysics involves relativistic systems. Therefore, Einstein's view of gravity is crucial to me. I consider the theory as the highest form of human creativity - just like the music of JS Bach. Over the past 100 years, the theory has been tested through various experiments and in different ways.
 
“The discovery of gravitational waves was the last hurdle to overcome in making this absolutely unfaltering. I am therefore thrilled by the discovery. It is absolutely astounding to imagine that the equations used to make the predictions about the gravitational-wave emissions when two gravitational whirlpools collide - as discovered on 14 September 2015 by LIGO - are basically Einstein's original equations that were published way back in 1916 - in other words, 100 years ago.
 
“The LIGO detectors have been operational since the early 1990s, but they had to undergo several stages of upgrades before being sensitive enough to make detections. LIGO is currently in its final stage, and is expected to function at optimal sensitivity only within a year or two. To be able to conduct the measurements at this stage is therefore a fantastic achievement, since much more funding will certainly be deposited in the project,” Prof Meintjes says.

Description: Prof Pieter Meintjes Tags: Prof Pieter Meintjes

Prof Pieter Meintjes
Photo: Charl Devenish

The search for gravitational waves by means of the Square Kilometre Array (SKA) is one of the focus points in research by both Prof Meintjes and PhD student, Jacques Maritz. This involves the study of radio signals from pulsars that might show signs of effects by gravitational waves. They are looking for signs of gravitational waves. The gravitational waves discovered and studied in this manner would naturally vary much more slowly than the signal discovered from the two colliding gravitational waves.
 
The discovery will definitely provide renewed impetus to the Square Kilometre Array (SKA) Project to use the dispersion of pulsar signals, and to search for the impact of gravitational waves on signals as they travel through the universe. According to Prof Meintjes, the SKA will definitely contribute fundamentally to the Frontier research, which will provide a good deal of publicity for the UFS and South Africa, if significant contributions are made by local researchers in this field.

Video clip explaining gravitational waves

 

  • The Department of Physics will present a general, non-technical talk concerning the recent detection of gravitational waves by the 2 Laser Interferometer Gravitational Wave Observatories (LIGO):

Wednesday 24 February 2016
11:00-12:00
New lecture auditorium, Department of Physics

 

 

 

 

 

 

 

 

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept